Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;56(1):420-7.
doi: 10.1128/AAC.05036-11. Epub 2011 Oct 17.

Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome

Affiliations

Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome

Isabel Sánchez-Romero et al. Antimicrob Agents Chemother. 2012 Jan.

Abstract

We study the epidemiology, molecular basis, clinical risk factors, and outcome involved in the clonal dissemination of VIM-1-producing Klebsiella pneumoniae isolates in the hospital setting. All patients infected/colonized by carbapenem-nonsusceptible K. pneumoniae (CNSKP) in 2009 were included. Molecular epidemiology was studied by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Antibiotic resistance genes were analyzed by PCR and sequencing. Plasmids were studied by PFGE with S1 nuclease digestion and for incompatibility group by a PCR-based replicon typing scheme. Risk factors associated with CNSKP colonization/infection were assessed by an observational case-control study. All 55 patients studied were infected (n = 28) or colonized (n = 27) by VIM-1-producing K. pneumoniae. All but one acquired isolates of a single clone (PFGE cluster 1 [C1], sequence type 15 [ST15]), while another clone (PFGE C2, ST340) was detected in four patients. C1 isolates also produced the new extended-spectrum β-lactamase SHV-134. bla(VIM-1) was carried in a class 1 integron and an untypeable plasmid of ∼50 bp. The number of days that the patient received mechanical ventilation, the use of parenteral nutrition, previous treatment with linezolid, and treatment with extended-spectrum cephalosporins for more than 7 days were detected to be independent risk factors for CNSKP acquisition. The VIM-1-producing K. pneumoniae ST15 clone has a high capacity to spread among intensive care unit patients with severe underlying conditions. A high rate of associated mortality and great difficulty in controlling the spread of this clone, without permanent behavioral changes in the personnel, were observed.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Dendrogram illustrating the PFGE profiles and MLST types of the two different clones of VIM-1-producing Klebsiella pneumoniae isolates and the number of patients infected and/or colonized by each. One patient was infected by clone C1/ST15 and colonized by clone C2/ST340. Two patients were colonized by both C1/ST15 and C2/ST340.
Fig 2
Fig 2
Epidemic curve of cases of infection by VIM-producing Klebsiella pneumoniae in two intensive care units. SICU-I, infected patients in surgical intensive care unit; MICU-I, infected patients in medical intensive care unit.

Similar articles

Cited by

References

    1. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. 2000. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am. J. Med. 108:609–613 - PubMed
    1. Cagnacci S, et al. 2008. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J. Antimicrob. Chemother. 61:296–300 - PubMed
    1. Carattoli A, et al. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods 63:219–228 - PubMed
    1. Carattoli A, et al. 2006. Replicon typing of plasmids encoding resistance to newer β-lactams. Emerg. Infect. Dis. 12:1145–1148 - PMC - PubMed
    1. Carmeli Y, et al. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin. Microbiol. Infect. 16:102–111 - PubMed

Publication types

MeSH terms